OCS OCULIS HOLDING AG

Oculis to Participate in Upcoming June Investor Conferences

Oculis to Participate in Upcoming June Investor Conferences

ZUG, Switzerland, June 03, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis will be participating in the following upcoming investor conferences:

Goldman Sachs Annual Healthcare Conference

June 9-11; Miami, FL, U.S.

Fireside chat with Riad Sherif, MD, Chief Executive Officer, on June 10th from 9:20 to 9:55am ET.

J.P. Morgan European Healthcare Conference

June 12; London, U.K.

Riad Sherif, MD, Chief Executive Officer, will be attending.

The Company will be available for one-on-one meetings during the conferences. Interested investors should contact their respective representative at the sponsoring institutions to request meetings.

Webcast links, when available, will be posted to the Oculis website on the  page under the Investors & Media section.

About Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs. Oculis’ highly differentiated pipeline of multiple innovative product candidates in development includes: OCS-01, a topical eye drop candidate for diabetic macular edema (DME); Privosegtor (OCS-05), a neuroprotective candidate for acute optic neuritis with potentially broad clinical applications in other neuro-ophthalmic diseases and Licaminlimab (OCS-02), a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.

For more information, please visit:

Oculis Contacts

Ms. Sylvia Cheung, CFO

Investor Relations

LifeSci Advisors

Corey Davis, Ph.D.

Media Relations

ICR Healthcare

Amber Fennell / David Daley / Sean Leous



EN
03/06/2025

Underlying

OCSOCULIS HOLDING AG

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OCULIS HOLDING AG

 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Upsized Loan Facility to Access up to CHF 100 million

Oculis Upsized Loan Facility to Access up to CHF 100 million ZUG, Switzerland, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that it has amended its loan facility (the “Amended Loan Agreement”) with funds and accounts managed by BlackRock (the “Lender”). The Amended Loan Agreement replaces the prior loan agreement between Oculis and the Lender dated May 29, 2024, an...

August 1, 2025 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis hækkar lánsheimild sína og fær aðgang að allt að 100 milljónum ...

Oculis hækkar lánsheimild sína og fær aðgang að allt að 100 milljónum CHF ZUG, Sviss, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) („Oculis“ eða „félagið“), alþjóðlegt líftæknifyrirtæki með áherslu á nýsköpun við meðferð á augn- og augntaugasjúkdómum í því skyni að mæta verulegum óuppfylltum læknisfræðilegum þörfum, greinir frá því í dag að breytingar hafa verið gerðar á lánssamningi félagsins („breytti lánssamningurinn“) við sjóði í stýringu hjá BlackRock („lánveitandi“). Breytti lánasamningurinn kemur í stað fyrri lánssamnings, sem gerður var þann 29. m...

August 1, 2025 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Upsized Loan Facility to Access up to CHF 100 million

Oculis Upsized Loan Facility to Access up to CHF 100 million ZUG, Switzerland, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that it has amended its loan facility (the “Amended Loan Agreement”) with funds and accounts managed by BlackRock (the “Lender”). The Amended Loan Agreement replaces the prior loan agreement between Oculis and the Lender dated May 29, 2024, an...

August 1, 2025 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Publishes Notifications of Transactions by Persons Discharging ...

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities ZUG, Switzerland, July 09, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to directors of the Company. Attachment

July 9, 2025 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Publishes Notifications of Transactions by Persons Discharging ...

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities ZUG, Switzerland, June 09, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to the annual equity incentive awards granted to directors of the Company. Attachments

June 9, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch